Launch HN: PostEra (YC W20) Medicinal Chemistry-as-a-Service and Covid Moonshot
What is medicinal chemistry? It’s part of discovering new drugs. A drug hunter decides what disease to focus on and then selects ‘targets’: usually proteins whose activity is key to the disease. Then they look for a molecule that can ‘hit’ that target and stimulate a response which will hopefully have beneficial effects. Developing such a molecule that is potent and safe is medicinal chemistry.
Despite it being a crucial part of drug development, this field has relied on trial-and-error approaches—a very expensive way to muddle toward a drug. Where computational tools have been used, they have emphasized the 'best' designs without any awareness of what it would take to physically make the drug in a lab and test it. Our approach is to apply computational methods that know how to make these designs.
We’ve been working on developing machine learning tools to advance the field for the last 3 years. Alpha formed a lab at Cambridge in 2017 to apply machine learning to drug discovery. Matt joined the group and soon some exciting results began to emerge, particularly in the area of how to make molecules. We published the first model to outperform trained human chemists in predicting the outcomes of chemical reactions. Alpha then got Aaron, his former mathematics classmate and debate partner at Oxford to leave his job for the world of drug discovery.
We decided to focus on the one challenge that exists at almost every step: molecules need to be made. No matter how clever it looks on paper, a molecule is worthless unless it can be tested in a lab. The task of actually making molecules, known as chemical synthesis, is often a challenging problem, involving the combinatorial explosion of games like Go with moves that can’t be defined in a simple rulebook.
You start with a set of simple molecules which can be combined through chemical reactions (a ‘move’) to form more and more complex molecules, known as the ‘route’, until you arrive at your desired drug candidate. But how to combine these molecules? Trial and error is not an option, given the enormous cost of doing chemistry, and just enumerating all options to a client is unhelpful given that your average molecule can have hundreds of theoretically-possible routes. Searching this tree of routes and scoring the viability of such routes is where ML becomes very powerful.
We developed a machine-translation approach which takes in reactants and outputs the product of a reaction; an approach very similar to how Google Translate operates. This allows us to score the viability of each move. We combine this with fast tree search algorithms, used in models like AlphaGo to efficiently search the large combinatorial space of possible reactions.
To get this technology in front of users, we're building a cloud-based platform. Clients input the molecule they want to be made, our system designs a route for how to make it, and then the client can order this molecule through our platform. We don’t own a lab, but we partner with chemical manufacturers around the world who execute the routes we design. Combining automated chemical synthesis with compound ordering creates a better experience for the drug hunter who wants to focus on their science and just wants a vial with their compound without the cumbersome process of figuring out how to make it and where to get it from.
All that is what we were working on until the pandemic hit... and now we can answer the second part of the title: COVID Moonshot.
We had just finished YC W20 when a tweet from a team of scientists quickly changed our travel (and company) trajectory. A team of scientists at Diamond Light Source in the UK had shown that a selection of chemical fragments were effective at binding to a key part...
40 comments
[ 2.6 ms ] story [ 98.7 ms ] threadIf I read this correctly, your team isn't discovering new drugs, but addressing the logistical need of building new compounds to make drugs, using ML to circumnavigate the most efficacious route to generate said compounds. Once complete, you actually outsource to manufacturers to build the compound molecules using your ML generated map.
Is that close?
Outside of this we also engage clients on more in-depth partnerships where we help design, make and test new drug candidates but again our real value-add/USP here is the 'make' stage.
Best of luck to your team and the project!
1) One big challenge in synthesis is ensuring compound purity. Even when I was working in pharma, it was often the case that some of the compounds in the screening library could be contaminated with intermediates. This is murder for any kind of anti-infectives research because you end up with false-positives for toxic intermediates. Since your assay is often, "does the compound kill the bug?" the answer for most chemicals is, "yes!". How do you ensure the purity of what you deliver to your customers? If I'm a medicinal chemist wanting to try this, I want to know that I'm not getting a vial of brick dust back.
2) Just because you have a mechanism to synthesize, doesn't mean the yield is going to be great. Does your algorithm factor in yield when selecting the route?
3) When I started reading your post I thought, "Hats off to these folks, this is a super hard problem that no shortage of extremely smart people have spent years trying to solve." Then I got to the moonshot section! The number of small molecule antiviral drugs with efficacy is vanishingly small. I understand why you would try to tackle this, but it truly is a moonshot.
4) I can't help but wonder what Derek Lowe (https://blogs.sciencemag.org/pipeline/) thinks of all this, have you guys tried to reach out to him?
2. Yes, our algorithm does factor in the yield when it decides which reaction to use.
3. You're absolutely right. It is very ambitious but we've realized that even if we don't get our compounds into human trials (currently aiming for in-vivo testing in next few weeks) that we will still have generated a lot of useful data that is there in the open for when the next pandemic comes around. This has been a real weakness from prior pandemic where research wasn't continued and certainly wasn't stored in clean accessible ways. As I'm sure you know SARS has super high genetic similarity to current COV-2 so having prior data accessible and cleaned would have given researchers a real head start.
4. Yes Derek is aware of COVID Moonshot and is also of the opinion that is it both ambitious but sadly necessary. We continue to follow his posts as healthy skepticism particularly in the area of AI for drug discovery is always helpful.
Inital thoughts - defining easy of synthetic pathway seems hard. If I'm an organic chemist and the recommended molecule involves a cost, technique or equipment that's inaccessible then I'd be stuck. However, if your network of manufactures can make it then labs may consider outsourcing it. I commonly see 10 to 1000x pricing differences in custom synthesis so there's also a risk of one vendor quoting too high and development prematurely stopping. For context and those that maybe outside this field, you can get a quote for over a million dollars for scaling up a product such as 100mg to 10g (not even a new route). You may need large amounts of the molecule for assay, animal testing, humans trials and going to market. Technique and equipment may not be an issue if your network is large enough, It will be interesting to see if you charge the drug companies as like a SaaS play and/or percent of sale from manufacturers like the YC company Science Exchange. Another idea is offering the software for free and make a percentage on the patent (IP) related the pathway.
Regarding pricing model this is something we are still working on. And yes you've hit the nail on the head -- We could charge the drug hunter (SaaS or IP) or we could charge the CROs that we send the custom synthesis to. Love to hear your thoughts here.
I would be cautious with chemical database (unsure which you are using) as there are companies that post chemicals as lead generation and cannot make them.
If you solve the selection of the best route, helping with sourcing the product may not be worth your resources. In other words, just that piece alone, if done well, is very valuable and hope the market sees it.
And you make a great point. We've been constantly reminded that virtual spaces created by CROs are not always executable. As such we can actually constrain our algorithms to require very high probability of reaction success to remove false positives. We then tell the CRO what building blocks they need and the route design. We're still figuring how much of the lifecycle of making molecules is worth going after or, if indeed as you say, the route itself is the key solution.
Ultimately when partnering with drug hunters, outside of our cloud-based platform, we offer the integration of molecular design with chemical synthesis as we believe computational approaches are at their most useful when these two aspects are coupled.
What is an "approved" drug development? Who gets to decide, when the substances are not restricted or scheduled? This means making them is not illegal. So I fail to see how it is an "unfortunate risk", except a risk of making money- which would be fortunate :)
You are missing opportunities just due to your specific moral stance. Drop-shipping is an excellent way to have new customer acquisition pipelines without having to pay for them.
Though please do correct me if I'm missing the use case you are referring to.
I think you may be throwing the baby with the bathwater, as designing and improving designer drugs is an untapped market with far more potential upsides than downsides.
React/Django/Postgres on AWS for APIs and websites. Terraform to manage the infrastructure. cortex.dev for serving some ML models, AWS Lambda for serving others. ML models are all PyTorch at the moment, with RDKit doing the chemistry heavy lifting. Data obtained through various means, including some tools from nextmovesoftware.com
There's a bunch more tech involved in supporting the scientists in the COVID moonshot, but that's basically everything ML-related.
Any particular part of the stack you were curious about?
apologies if this is wildly inaccurate, but is it fair to characterize your startup as helping people create custom drugs the same way ARM helped people create custom chips? from the outside, it seems like there could be intriguing parallels.
But yes, we are very interested in helping people get made what they want to get made. It often falls into two situations:
(1) If the customer knows exactly the custom design they want to get made, we can help them find the best way to purchase or synthesize it. In many cases, customers may have trouble coordinating with CROs themselves, finding the best building blocks and route to the molecule, and dealing with logistics. We try to help ease that pain.
(2) The customer has a specific target they want to hit and they need just the right small molecule to "fit" in it. We also help with this, mainly through partnerships. And our thinking is that good design of small molecule inhibitors (such as one targeting the COVID main protease) involves expert knowledge of what can be quickly made and tested to help guide further design.
Lastly, we also work on suggesting molecules that may be slightly different from what the customer thinks they want, but may show similar activity -- and will be much easier to make.
in the end, if your value tilts more toward logistics than IP, you may want to mine chemistry.com (?) for lessons, a startup from the dot-com boom funded by john doerr and kleiner perkins. the grand vision was to disrupt and streamline the logistics of the chemical industry.
If the article is correct, high costs for building and maintaining the "Amazon for chemicals" were the primary cause of failure.
Many great ideas are a matter of when, not if. Knowing when to launch is as critical for entrepreneurs as is knowing when to buy for investors.
A modern Chemdex might thrive like the modern Webvan (ie Instacart) because if costs were the cause of death, a cloud infrastructure would address this issue.
Obviously, this is a very different model from the ARM model.
Hopefully one of these comparisons can offer helpful insights.